|
COMMERCE BUSINESS DAILY ISSUE OF JUNE 1,2000 PSA#2612NCI Frederick Cancer Research and Development Center (NCI-FCRDC), P.O.
Box B, Frederick, Maryland 21702-1201 A -- CGMP PRODUCTION OF RECOMBINANT HERPES SIMPLEX VIRUS CONSTRUCTS
SOL S00-168 DUE 061300 POC Thomas L. Danver, Sr. Contract Specialist at
301-846-5422; Terry W. Hebb, Sr. Contracts Advisor at 301-846-5416
E-MAIL: Click here to contact the contract specialist via,
tdanver@mail.ncifcrf.gov. The National Cancer Institute's (NCI) new
Rapid Access To Intervention Development program (RAID) program is
designed to utilize NCI contract resources to assist extramural
investigators with the preclinical and clinical development
requirements for drugs and biologics that will be used in clinical
trials. As part of this new initiative, the NCI wishes to identify
qualified Offerors, who can produce clinical-grade Herpes Simplex Virus
(HSV) constructs for use in vaccine clinical trials. As part of this
new initiative, the NCI wishes to find new contract resources that are
capable of manufacture, purification, formulation, and vialing Herpes
constructs under current Good Manufacturing Practices (cGMPs)
appropriate for phase I/II clinical trials. The NCI will provide the
recombinant Herpes Simplex vector containing the DNA sequence of
interest. In addition, the NCI will provide information on the
formulation and vialing requirements of all products. Offerors should
have experience in the cGMP manufacturing and vialing of clinical-grade
Herpes Simplex virus and/or viral products for clinical trials. The
contractor will be required to provide a Certificate Of Analysis (COA),
which provides data that support the identity, composition, purity,
potency, and safety of the requested products. In addition, the NCI
should have the opportunity to cross-reference the contractor=s Drug
Master File for IND purposes. Interested companies should describe
their capabilities and experience and respond by June 13, 2000 to
Thomas L. Danver. Posted 05/26/00 (W-SN459382). (0147) Loren Data Corp. http://www.ld.com (SYN# 0011 20000601\A-0011.SOL)
A - Research and Development Index Page
|
|